Company Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease.
In addition, the company’s pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101.
It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis.
Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2020 |
| IPO Date | Dec 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Arun Swaminathan |
Contact Details
Address: 5850 San Felipe St., Suite 500 Houston, Texas 77057 United States | |
| Phone | 800 587 8170 |
| Website | coyatherapeutics.com |
Stock Details
| Ticker Symbol | COYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001835022 |
| ISIN Number | US22407B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arun Swaminathan Ph.D. | Chief Executive Officer and Director |
| Dr. Howard H. Berman Ph.D. | Executive Chair |
| Dr. Fred Grossman D.O., FAPA | President and Chief Medical Officer |
| David S. Snyder | Chief Financial Officer and Chief Operating Officer |
| Dr. Michelle Frazier Ph.D. | Senior Vice President of Regulatory Affairs |
| Aaron Thome Ph.D. | Head of Neuroinflammation Platform |
| Karen King M.S. | Senior Vice President of Program Management and Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 8-K | Current Report |
| May 16, 2025 | ARS | Filing |
| May 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 10-K/A | [Amend] Annual report |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |